

# in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

## General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iiarjournals.org](http://www.iiarjournals.org)

## Selection of Recent Articles

Repopulation of the Irradiation Damaged Lung with Bone Marrow-derived Cells. M.E. BERNARD, H. KIM, M.S. RAJAGOPALAN, B. STONE, U. SALIMI, J.-C. RWIGEMA, M.W. EPPERLY, H. SHEN, J.U.P. GOFF, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, H. WANG, D.B. STOLZ, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

15-Lipoxygenase-1 Induces Lipid Peroxidation and Apoptosis, and Improves Survival in Rat Malignant Glioma. H. VIITA, A. PACHOLSKA, F. AHMAD, J. TIETÄVÄINEN, J. NAARALA, A. HYVÄRINEN, T. WIRTH, S. YLÄ-HERTTUALA (*Kuopio; Joensuu, Finland*)

Identification of Four Isoforms of Aldolase B Down-regulated in Hepatocellular Carcinoma Tissues by Means of Two-dimensional Western Blotting. Y. WANG, Y. KURAMITSU, M. TAKASHIMA, Y. YOKOYAMA, N. IIZUKA, T. TAMESA, I. SAKAIDA, M. OKA, K. NAKAMURA (*Ube, Japan*)

Effects of Polo-like-kinase-1-inhibitor BI 2536 in Squamous Cell Carcinoma Cell lines of the Head and Neck- first In Vitro Results. J. WAGENBLAST, D. HIRTH, L. THRON, C. ARNOLDNER, M. DIENSTHUBER, T. STÖVER, M. HAMBEK (*Frankfurt am Main, Germany; Vienna, Austria*)

Expression Patterns and Potential Action of the Calcium Transport Genes Trpv5, Trpv6, Ncx1 and Pmca1b in the Canine Duodenum, Kidney and Uterus. J.-A. KIM, H. YANG, I. HWANG, E.-M. JUNG, K.-C. CHOI, E.-B. JEUNG (*Chungbuk, Republic of Korea*)

Association of IGF Axis Hormones with Waist-to-Hip Ratio Varies by Physical Activity. K.H. SCHMITZ, D. XIE, V. TEAL, R. BALLARD-BARBASH, D. BERRIGAN (*Philadelphia, PA; Bethesda, MD, USA*)

Post-operative Corticosterone Levels in Plasma and Feces of Mice Subjected to Permanent Catheterization and Automated Blood Sampling. R. SUNDBOM, K.R. JACOBSEN, O. KALLIOKOSKI, J. HAU, K.S.P. ABELSON (*Uppsala, Sweden; Copenhagen, Denmark*)

Familial Hodgkin's Lymphoma in Scandinavia. V. JÖNSSON, H. AWAN, E. NYQUIST, M. MAISENHÖLDER, T.B. JOHANNESSEN, B. LY, G.E. TJØNNFJORD (*Oslo, Norway*)

Repair of Postauricular Defects Using a New Technique: The Swallowtail Flap. C. MONARCA, M. MARUCCIA, F. PALUMBO, N. SCUDERI (*Rome, Italy*)

Adipocyte-derived Factor as a Modulator of Oxidative Estrogen Metabolism: Implications for Obesity and Estrogen-dependent Breast Cancer. H.L. BRADLOW, D.W. SEPKOVIC, N. TELANG, R. TIWARI (*New York, NY, USA*)

No Cytomegalovirus Detected in the Gastrointestinal Tract of Patients with Active Crohns Disease. M.T. AARNIO, J.P. BÖHM, K.P. NUORVA, R.I. PITKÄNEN, T.H. KUOPIO, M.E. VOUTILAINEN (*Jyväskylä, Finland*)

Colon Cancer Vaccines: An Update (Review). E. MERIKA, M.W. SAIF, A. KATZ, C. SYRIGOS, M. MORSE (*London, UK; Haven, CT; Durham, NC, USA; Athens, Greece*)

Animal Models of N-Methyl-N-Nitrosourea-induced Mammary Cancer and Retinal Degeneration with Special Emphasis on Therapeutic Trials (Review). A. TSUBURA, OY.-C. LAI, H. MIKI, T. SASAKI, N. UEHARA, T. YURI, K. YOSHIZAWA (*Moriguchi, Osaka, Japan*)

Canine Mammary Tumours as a Model to Study Human Breast Cancer: Most Recent Findings (Review). F.L. QUEIROGA, T. RAPOSO, M.I. CARVALHO, J. PRADA, I. PIRES (*Vila Real, Portugal*)

Metastatic Potential of Orthotopic and Heterotopic Models Imaged by GFP and RFP Protein (Review). V. BOBEK, K. KOLOSTOVA, D. PINTEROVA, M. BOUBELIK, R. GURLICH, R.M. HOFFMAN (*Prague, Czech Republic; San Diego, CA, USA*)

Serotonin Transporter Polymorphism in Major Depressive Disorder (MDD), Psychiatric Disorders, and in MDD in Response to Stressful Life Events: Causes and Treatment with Antidepressant (Review). A. DANIELE, R. DIVELLA, A. PARADISO, V. MATTIOLI, F. ROMITO, F. GIOTTA, P. CASAMASSIMA, M. QUARANTA (*Bari, Italy*)

In Vivo Research Using Early Life Stage Models (Review). R. SEABRA, N. BHOGAL (*Nottingham, UK*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

## Instructions to Authors

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

*Tables.* Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

*References.* Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinassios  
 International Institute of Anticancer Research (IIAR)  
 Editorial Office of ANTICANCER RESEARCH,  
 IN VIVO, CANCER GENOMICS and PROTEOMICS.  
 1st km Kapandritiou-Kalamou Road  
 P.O. Box 22, GR-19014 Kapandriti, Attiki  
 GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

*Reprints.* Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

# CANCER GENOMICS & PROTEOMICS

www.cgp-iiarjournals.com

Print ISSN: 1109-6535  
Online ISSN: 1790-6245  
VOL. 1 (2004) - VOL. 9 (2012)



**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**: For more information please visit our websites [www.cgp-journals.com](http://www.cgp-journals.com); [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iiarjournals.org](http://www.iiarjournals.org).

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. e-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org); IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iiarjournals.org](http://www.iiarjournals.org)

**Free specimen copies of CGP are available on request.**

## A Selection of Recent Papers

KRAS Mutation is Associated with Elevated Myeloblastin Activity in Human Lung Adenocarcinoma. T. WIEDL, S. COLLAUD, S. HILLINGER, S. ARNI, C. BURGESS, W. KROLL, P. SCHRAML, A. SOLTERMANN, H. MOCH, W. WEDER (*Zurich, Switzerland; Cambridge, MA, USA*)

Early detection of Ovarian Cancer in Pre-diagnosis Samples Using CA125 and MALDI MS Peaks. J.F. TIMMS *et al* (*London; Reading, UK*)

Decoding Differentially Regulated Epithelial and Stromal Pathways in Colorectal Cancer. M. ABBA, S. LAUFS, M. AGHAJANY, B. KORN, A. BENNER, H. ALLGAYER (*Heidelberg, Germany*)

New Gene Groups Associated with Dissimilar Osteoblastic Differentiation Are Linked to Osteosarcomagenesis. F. LUK, Y. YU, H.- T. DONG, W.R. WALSH, J.- L. YANG (*Sydney, NSW, Australia*)

Small Molecule Inhibition of Cytoskeletal Dynamics in Melanoma Tumors Results in Altered Transcriptional Expression Patterns of Key Genes Involved in Tumor Initiation and Progression. C. SPENCER, J. MONTALVO, S.R. MCLAUGHLIN, B.A. BRYAN (*Worcester, MA, USA*)

Gene Expression Profile Can Predict Pathological Response to Preoperative Chemoradiotherapy in Rectal Cancer. M. NISHIOKA, M. SHIMADA, N. KURITA, T. IWATA, S. MORIMOTO, K. YOSHIKAWA, J. HIGASHIJIMA, T. MIYATANI (*Tokushima, Japan*)

Gene Expression Profiling and its Utility in Prediction of Local Relapse after Breast-conserving Therapy in Early Breast Cancer. R. SABATIER, P. FINETTI, N. CERVERA, A. TALLET, M. BENCHALAL, G. HOUVENAEGHEL, J. JACQUEMIER, D. BIRNBAUM, F. BERTUCCI (*Marseille; Rennes, France*)

Restoration of Senescence in Breast and Ovarian Cancer Cells Following the Transfer of the YAC Carrying SEN6A Gene Located at 6q16.3. N.S. RANE, A.K. SANDHU, V.S. ZHAWAR, G. KAUR, N.C. POPESCU, R.P. KANDPAL, M. JHANWAR-UNIYAL, R.S. ATHWAL (*Philadelphia, PA; Bethesda, MD; Pomona, CA; Valhalla, NY, USA*)

Therapy-, Gender- and Race- specific microRNA Markers, Target Genes and Networks Related to Glioblastoma Recurrence and Survival. K.R. DELFINO, N.V.L. SERÃO, B.R. SOUTHEY, S.L. RODRIGUEZ- ZAS (*Urbana, IL, USA*)

Differential Splicing Generates New Transmembrane Receptor and Extracellular Matrix-related Targets for Antibody-based Therapy of Cancer (Review). U.H. WEIDLE, D. MAISEL, S. KLOSTERMANN, E.H. WEISS, M. SCHMITT (*Penzberg; Planegg-Martinsried; Munich, Germany*)

The Cancer Biomarker Osteopontin: Combination with Other Markers (Review). G.F. WEBER (*Cincinnati, OH, USA*)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma (Review). T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (*Düsseldorf, Germany*)

TGF-  $\beta$ 1 Interactome: Metastasis and Beyond (Review). M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO- MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAL, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (*Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA*)

Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer (Review). N. VALERI, C.M. CROCE, M. FABBRI (*Columbus, OH, USA; Ferrara; Meldola, Italy*)

The Continuing Search for Predisposing Colorectal Cancer Variants (Review). S. PICELLI, S. VON HOLST, P. WESSENDORF (*Stockholm, Sweden*)

Extravasation of Liposomal Doxorubicin Induces Irritant Reaction without Vesicant Injury. E. CURTIT, L. CHAIGNEAU, J. PAUCHOT, T. NGUYEN, V. NERICH, F. BAZAN, A. THIERY-VUILLEMIN, M. DEMARCHI, X. PIVOT, C. VILLANUEVA ( <i>Besançon, France</i> ) .....	1481
Complete Response and Long-term Survival in Malignant Pleural Mesothelioma: Case Report. S. TAKANEN, B. RESULI, V. GRAZIANO, A. PARISI, R. LISI, N. RAFFETTO, V. TOMBOLINI ( <i>Rome, Italy</i> ).....	1485
Study of AP Endonuclease (APEX1/REF1), a DNA Repair Enzyme, in Gallbladder Carcinoma. V.K. SHUKLA, P.C. DAS, R. DIXIT, S.K. BHARTIYA, S. BASU, M.J. RAMAN ( <i>Varanasi, India</i> ) .....	1489
Adjuvant Intravesical Instillation for Primary T1G3 Bladder Cancer: BCG versus MMC in Korea. I.-C. CHO, E.K. KIM, J.Y. JOUNG, H.K. SEO, J. CHUNG, W.S. PARK, K.H. LEE ( <i>Goyang, South Korea</i> ) .....	1493
Investigative Clinical Study on Prostate Cancer Part VIII: Prolactin Hormone and the Pituitary-Testicular-Prostate Axis at the Time of Initial Diagnosis and Subsequent Cluster Selection of the Patient Population after Radical Prostatectomy. A.B. PORCARO, C. GHIMENTON, A. PETROZZIELLO, F. MIGLIORINI, M. ROMANO, T. SAVA, B. CARUSO, C. COCCO, S.Z. ANTONIOLLI, V. LACOLA, E. RUBILOTTA, C. MONACO, L. COMUNALE ( <i>Verona, Italy</i> ) .....	1499
PKC $\eta$ Is a Novel Prognostic Marker in Non-small Cell Lung Cancer. E. KRASNITSKY, Y. BAUMFELD, J. FREEDMAN, N. SION-VARDY, S. ARIAD, V. NOVACK, E. LIVNEH ( <i>Beer Sheva, Israel</i> ) .....	1507
Ameloblastic Carcinoma, Primary Type: Case Report, Immunohistochemical Analysis and Literature Review. A.R. CASAROTO, G.L. TOLEDO, J.L. TOLEDO-FILHO, C.T. SOARES, M.M. CAPELARI, V.S. LARA ( <i>Bauru, SP, Brazil</i> ).....	1515
Correlation of <i>MACC1</i> and <i>MET</i> Expression in Rectal Cancer after Neoadjuvant Chemoradiotherapy. M. KAWAMURA, S. SAIGUSA, Y. TOIYAMA, K. TANAKA, Y. OKUGAWA, J. HIRO, K. UCHIDA, Y. MOHRI, Y. INOUE, M. KUSUNOKI ( <i>Mie, Japan</i> ) .....	1527
A Two-step Selection of Breast Cancer Patients Candidates for Exclusive IORT with Electrons: A Mono-institutional Experience. M. GUENZI, A. FOZZA, G. TIMON, L. BELGIOIA, G. VIDANO, F. CAVAGNETTO, S. AGOSTINELLI, M. GUSINU, F. CARLI, F. CAFIERO, D. FRIEDMAN, G. CANAVESE, R. CORVÒ ( <i>Genoa, Italy</i> ) .....	1533
Impact of Epidural Analgesia on Survival in Patients Undergoing Complete Cytoreductive Surgery for Ovarian Cancer. P. CAPMAS, V. BILLARD, S. GOUY, C. LHOMMÉ, P. PAUTIER, P. MORICE, C. UZAN ( <i>Villejuif, France</i> ).....	1537
Lip Cancer: A 10-Year Retrospective Epidemiological Study. M. MARUCCIA, M.G. ONESTI, P. PARISI, E. CIGNA, A. TROCCOLA, N. SCUDERI ( <i>Rome, Italy</i> ) .....	1543
The Prognostic Significance of HER2 Positivity for Advanced Gastric Cancer Patients Undergoing First-line Modified FOLFOX-6 Regimen. J.W. KIM, S.-A. IM, M. KIM, Y. CHA, K.-H. LEE, B. KEAM, M.A. KIM, S.-W. HAN, D.-Y. OH, T.-Y. KIM, W. H. KIM, Y.-J. BANG ( <i>Seoul, Republic of Korea</i> ) .....	1547
Pretreatment Neutrophil:Lymphocyte Ratio as a Prognostic Factor in Cervical Carcinoma. Y.-Y. LEE, C.H. CHOI, H.-J. KIM, T.J. KIM, J.W. LEE, J.-H. LEE, D.-S. BAE, B.-G. KIM ( <i>Seoul, Republic of Korea</i> ) .....	1555
Errata .....	1563

\* Reviews (pages 1119, 1379)



Intra-arterial Infusion of Irinotecan-loaded Drug-eluting Beads (DEBIRI) versus Intravenous Therapy (FOLFIRI) for Hepatic Metastases from Colorectal Cancer: Final Results of a Phase III Study. G. FIORENTINI, C. ALIBERTI, M. TILLI, L. MULAZZANI, F. GRAZIANO, P. GIORDANI, A. MAMBRINI, F. MONTAGNANI, P. ALESSANDRONI, V. CATALANO, P. COSCHIERA ( <i>Pesaro; Padova; Ferrara; Carrara; Biella, Italy</i> ) .....	1387
Adjuvant Chemoradiation with 5-Fluorouracil or Capecitabine in Patients with Gastric Cancer after D2 Nodal Dissection. M.F. OSTI, L. AGOLLI, S. BRACCI, F. MONACO, S. TUBIN, G. MINNITI, V. DE SANCTIS, R.M. ENRICI ( <i>Rome, Italy</i> ) .....	1397
Phase II Study of Docetaxel, Cisplatin and 5-Fluorouracil (DCF) for Metastatic Esophageal Cancer (OGSG 0403). S. TAMURA, M. IMANO, H. TAKIUCHI, K. KOBAYASHI, H. IMAMOTO, H. MIKI, Y. GOTO, T. AOKI, Y.-F. PENG, T. TSUJINAKA, H. FURUKAWA ( <i>Hyogo; Osaka, Japan</i> ) .....	1403
C-Reactive Protein is Associated with Distant Metastasis of T3 Colorectal Cancer. M. ISHIZUKA, H. NAGATA, K. TAKAGI, K. KUBOTA ( <i>Tochigi, Japan</i> ) .....	1409
Factors Resulting in 5-Year Disease-free Survival after Resection of Hepatocellular Carcinoma. T. OCHIAI, H. IKOMA, Y. MURAYAMA, A. SHIOZAKI, S. KOMATSU, Y. KURIU, M. NAKANISHI, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, Y. KOKUBA, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	1417
Long-term Amrubicin Chemotherapy for Small-cell Lung Cancer. M. HIGASHIGUCHI, H. SUZUKI, T. HIRASHIMA, M. KOBAYASHI, S. GOYA, N. OKAMOTO, Y. MATSUURA, M. TAMIYA, N. MORISHITA, I. KAWASE ( <i>Osaka, Japan</i> ) .....	1423
Elevated HER2 Extracellular Domain Level in Primary Breast Cancer with HER2 Overexpression Predicts Early Failure of Adjuvant Trastuzumab. S. THUREAU, F. CLATOT, S. LABERGE-LE-COUTEULX, M. BARON, J.-P. BASUYAU, E. BLOT ( <i>Rouen; Vannes, France</i> ) .....	1429
Lymphoepithelioma-like Carcinoma of the Breast: A Case Report with a Special Analysis of an Association with Human Papilloma Virus. Y. NIO, K. TSUBOI, M. TAMAOKI, M. TAMAOKI, R. MARUYAMA ( <i>Kyoto; Izumo, Japan</i> ) .....	1435
Histopathological Classification of <i>Pseudomyxoma Peritonei</i> and the Prognostic Importance of PINCH Protein. H. ANDRÉASSON, A. WANDERS, X.-F. SUN, R. WILLÉN, W. GRAF, P. NYGREN, B. GLIMELIUS, Z.-Y. ZHANG, H. MAHTEME ( <i>Uppsala; Linköping; Stockholm, Sweden; Tangshan, PR China</i> ) .....	1443
Secondary Tumors of the Pancreas: A Case Series. B. PAN, Y. LEE, T. RODRIGUEZ, J. LEE, M.W. SAIF ( <i>New York, NY, USA</i> ) .....	1449
Nedaplatin and Irinotecan in Patients with Large-cell Neuroendocrine Carcinoma of the Lung. Y. KENMOTSU, F. OSHITA, M. SUGIURA, S. MURAKAMI, T. KONDO, H. SAITO, K. YAMADA ( <i>Yokohama, Japan</i> ) .....	1453
Comparison of the Chemosensitivity of the Primary Lesion and a Pancreatic Metastasis of Colon Cancer: A Case Report. H. TAMAGAWA, Y. MIYAGI, M. NUMATA, N. YAMAMOTO, M. SHIOZAWA, S. MORINAGA, A. SEKIYAMA, H. SEKIGUCHI, Y. SAKUMA, Y. KAMEDA, M. AKAIKE, M. MASUDA, T. IMADA ( <i>Yokohama, Japan</i> ) .....	1457
A Modified Vimentin Histological Score Helps Recognize Pulmonary Sarcomatoid Carcinoma in Small Biopsy Samples. G. PELOSI, F. MELOTTI, A. CAVAZZA, G. ROSSI, P. MAISONNEUVE, P. GRAZIANO, M. BARBARESCHI, Y. NAKATANI, M. PAPOTTI ( <i>Milan; Reggio Emilia; Modena; Rome; Trento; Orbassano, Italy; Chiba, Japan</i> ) .....	1463
Concurrent Chemoradiotherapy with Paclitaxel and Cisplatin for Adenocarcinoma of the Cervix. Y. NAGAI, T. TOITA, A. WAKAYAMA, T. NAKAMOTO, T. OYAMA, A. TOKURA, M. INAMINE, W. KUDAKA, S. MURAYAMA, Y. AOKI ( <i>Okinawa, Japan</i> ) .....	1475

The Relationship between Secretary Leukocyte Protease Inhibitor Expression and Epstein-Barr Virus Status among Patients with Nasopharyngeal Carcinoma. K.-P. TSE, C.-S. WU, C. HSUEH, K.-P. CHANG, S.-P. HAO, Y.-S. CHANG, N.-M. TSANG ( <i>Taoyuan; Taipei, Taiwan, ROC</i> ) .....	1299
Treatment of Breast Cancer Cells by IGF1R Tyrosine Kinase Inhibitor Combined with Conventional Systemic Drugs. H. HARTOG, W.T.A. VAN DER GRAAF, H.M. BOEZEN, J. WESSELING ( <i>Groningen; Nijmegen; Amsterdam, Netherlands</i> ) .....	1309
Methylation of the <i>DFNA5</i> Gene is Frequently Detected in Colorectal Cancer. K. YOKOMIZO, Y. HARADA, K. KIJIMA, K. SHINMURA, M. SAKATA, K. SAKURABA, Y. KITAMURA, A. SHIRAHATA, T. GOTO, H. MIZUKAMI, M. SAITO, G. KIGAWA, H. NEMOTO, K. HIBI ( <i>Yokohama, Japan</i> ) .....	1319
Oncogramme Responses of Breast Tumour Cells Treated with Herceptin Correlate with HER2/C-ERB B2 Pathological Status. S. GIRAUD, C. BOUNAIX MORAND DU PUCH, V. FERMEAUX, A. GUILLAUDEAU, C. LAUTRETTE ( <i>Limoges, France</i> ) .....	1323
<i>Clinical Studies</i>	
A Pilot Study of Letrozole for One Year in Women at Enhanced Risk of Developing Breast Cancer: Effects on Mammographic Density. J. SMITH, A. DILAWARI, G. URSIN, E. ANDREOPOULOU, C. CHECKA, D. AXELROD, A. GUTH, H. TOTH, M. UTATE, K. CARAPETYAN, E. REICH, T. DIFLO, F. MUGGIA ( <i>New York, NY; Los Angeles, CA, USA</i> ) .....	1327
A Prospective Clinical Trial of Cholecalciferol 2000 IU/day in Colorectal Cancer Patients: Evidence of a Chemotherapy-response Interaction. M.G. FAKIH, C. ANDREWS, J. MCMAHON, J.R. MUINDI ( <i>Ann Arbor, MI; Buffalo, NY, USA</i> ) .....	1333
The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy. G. HOLGERSSON, M. SANDELIN, E. HOYE, S. BERGSTRÖM, R. HENRIKSSON, S. EKMAN, J. NYMAN, M. HELSING, S. FRIESLAND, O. BRODIN, M. HOLGERSSON, K. LAMBERG LUNDSTRÖM, C. JANSON, L. EKBERG, C. MÖRTH, T. BLYSTAD, S.-B. EWERS, B. LÖDEN, M. BERGQVIST ( <i>Uppsala; Gävle; Umeå; Göteborg; Örebro; Stockholm; Malmö; Eskilstuna; Linköping; Lund; Karlstad, Sweden</i> ) .....	1339
Low-dose Cytarabine plus Aclarubicin for Patients with Previously Untreated Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Ineligible for Standard-dose Cytarabine plus Anthracycline. T. FUKUSHIMA, H. KAWABATA, T. SAWAKI, T. SATOH, T. NAKAMURA, H. IWAO, A. NAKAJIMA, T. SAKAI, M. MIKI, Y. FUJITA, M. TANAKA, T. KAWANAMI, Y. MASAKI, T. OKAZAKI, H. UMEHARA ( <i>Ishikawa; Kyoto, Japan</i> ) .....	1347
Sarcoidosis in a Patient with Metastatic Melanoma Sequentially Treated with Anti-CTLA-4 Monoclonal Antibody and Selective BRAF Inhibitor. S. WILGENHOF, V. MORLION, A.C. SEGHERS, S. DU FOUR, E. VANDERLINDEN, S. HANON, F. VANDENBROUCKE, H. EVERAERT, B. NEYNS ( <i>Brussels, Belgium</i> ) .....	1355
Expression of Serotonin Receptors 5-HT1A, 5-HT1B, 5-HT2B and 5-HT4 in Ovary and in Ovarian Tumours. R. HENRIKSEN, N. DIZEYI, P.-A. ABRAHAMSSON ( <i>Malmö, Sweden</i> ) .....	1361
Expression and Function of <i>FRA2/JUND</i> in Cutaneous T-Cell Lymphomas. T. NAKAYAMA, T. HIGUCHI, N. OISO, A. KAWADA, O. YOSHIE ( <i>Osaka, Japan</i> ) .....	1367
Retinal Neovascularization and Hemorrhage Associated with the Use of Imatinib (Gleevec®) in a Patient Being Treated for Gastrointestinal Stromal Tumor (GIST). A.P. GULATI, M.W. SAIF ( <i>New York, NY, USA</i> ) .....	1375
* Review: Improved Chemotherapy for Hepatocellular Carcinoma. H. CAO, H. PHAN, L.-X. YANG ( <i>San Francisco, CA, USA</i> ) .....	1379

Physiological Concentrations of Genistein and 17 $\beta$ -Estradiol Inhibit MDA-MB-231 Breast Cancer Cell Growth by Increasing BAX/BCL-2 and Reducing pERK1/2. T.T. RAJAH, K.J. PEINE, N. DU, C.A. SERRET, N.R. DREWS ( <i>Chicago, IL, USA</i> ) .....	1181
5-Aminosalicylic Acid Mediates Expression of Cyclooxygenase-2 and 15-Hydroxyprostaglandin Dehydrogenase to Suppress Colorectal Tumorigenesis. J. MIYOSHI, T. YAJIMA, K. SHIMAMURA, K. MATSUOKA, S. OKAMOTO, H. HIGUCHI, S. FUNAKOSHI, H. TAKAISHI, T. HIBI ( <i>Tokyo, Japan</i> ) .....	1193
Effective Targeting of the Tumor Microenvironment for Cancer Therapy. P. JIANG, X. LI, C.B. THOMPSON, Z. HUANG, F. ARAIZA, R. OSGOOD, G. WEI, M. FELDMANN, G.I. FROST, H.M. SHEPARD ( <i>San Diego, CA, USA; London, UK</i> ) .....	1203
Efficacy of the Chinese Traditional Medicinal Herb <i>Celastrus orbiculatus</i> Thunb on Human Hepatocellular Carcinoma in an Orthotopic Fluorescent Nude Mouse Model. M. WANG, X. ZHANG, X. XIONG, Z. YANG, Y. SUN, Z. YANG, R.M. HOFFMAN, Y. LIU ( <i>Nanjing; Yangzhou, PR China; San Diego, CA, USA</i> ) .....	1213
CK20 Expression Enhances the Invasiveness of Tamoxifen-resistant MCF-7 Cells. Y.S. MIN, E.H. YI, J.K. LEE, J.W. CHOI, J.H. SIM, J.-S. KANG, Y.-N. KIM, Y.-S. JUHNN, H.-R. KIM, S.-K. YE ( <i>Seoul; Gyeonggi-do, Republic of Korea</i> ) .....	1221
COM-1/p8 Acts as a Tumour Growth Enhancer in Colorectal Cancer Cell Lines. X. LI, T.A. MARTIN, W.G. JIANG ( <i>Cardiff, UK; Beijing, PR China</i> ) .....	1229
Radiosensitization of p53-Deficient Lung Cancer Cells by Pre-treatment with Cytostatic Compounds. S.V. TOKALOV, N. ABOLMAALI ( <i>Dresden, Germany; Bunyola, Balearic Islands, Spain</i> ) .....	1239
Molecular Characterization of Human Cutaneous Melanoma-derived Cell Lines. Z. OGBAH, J.A. PUIG-BUTILLE, F. SIMONETTA, C. BADENAS, R. CERVERA, J. MILÁ, D. BENITEZ, J. MALVEHY, R. VILELLA, S. PUIG ( <i>Barcelona, Spain</i> ) .....	1245
Human Papillomavirus Molecular Testing in Women with Low Grade Cervical Lesions: Experience from an Italian Hospital. P. PABA, C. ASCONE, A.A. CRISCUOLO, F. MARCUCCILLI, M. CICOZZI, F. SESTI, E. PICCIONE, C.F. PERNO, M. CIOTTI ( <i>Rome, Italy</i> ) .....	1253
Comparison of Genomic Signatures of Non-small Cell Lung Cancer Recurrence between Two Microarray Platforms. J.W.-C. CHANG, N.-C. WEI, H.-J. SU, J.-L. HUANG, T.-C. CHEN, Y.-C. WU, C.-T. YU, M.-M. HOU, C.-H. HSIEH, J.-J. HSIEH, C.-E. WU, H.-Y. CHENG, T. HSU, T.-H. WANG ( <i>Taoyuan; Hsinchu; Keelung, Taiwan, ROC</i> ) .....	1259
Enhanced siRNA Delivery Using Oleic Acid Derivative of Polyethylenimine. L. TENG, J. XIE, L. TENG, R.J. LEE ( <i>Jilin, PR China; Columbus, OH, USA</i> ) .....	1267
Immunohistochemical Study of the Epithelial-Mesenchymal Transition Phenotype in Cancer of Unknown Primary: Incidence, Correlations and Prognostic Utility. A. STOYIANNI, A. GOUSSIA, G. PENTHEROUDAKIS, V. SIOZOPOULOU, E. IOACHIM, D. KRIKELIS, V. GOLFINOPOULOS, A. CERVANTES, M. BOBOS, T. FOTSIS, S. BELLOU, G. FOUNTZILAS, V. MALAMOU-MITSI, N. PAVLIDIS ( <i>Ioannina; Athens; Thessaloniki, Greece; Valencia, Spain</i> ) .....	1273
EPLIN- $\alpha$ Expression in Human Oesophageal Cancer and its Impact on Cellular Aggressiveness and Clinical Outcome. Y. LIU, A.J. SANDERS, L. ZHANG, W.G. JIANG ( <i>Cardiff, UK; Beijing, China</i> ) .....	1283
Rapid, Laser-Induced Conversion of 20-Hydroxyecdysone and its Diacetone – Experimental Set-up of a System for Photochemical Transformation of Bioactive Substances. A. HUNYADI, B. DANKO, M. BONI, A. MILITARU, T. ALEXANDRU, V. NASTASA, I. R. ANDREI, M. L. PASCU, L. AMARAL ( <i>Szeged, Hungary; Bucharest, Romania; Lisbon, Portugal</i> ) .....	1291